Loading...

Catalyst Pharmaceuticals

DB:CN2
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CN2
DB
$546M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Catalyst Pharmaceuticals has significant price volatility in the past 3 months.
CN2 Share Price and Events
7 Day Returns
-5.6%
DB:CN2
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
128.2%
DB:CN2
-10.6%
DE Biotechs
-6.2%
DE Market
CN2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Catalyst Pharmaceuticals (CN2) -5.6% 52.6% 104.8% 128.2% 341.9% 217.2%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • CN2 outperformed the Biotechs industry which returned -10.6% over the past year.
  • CN2 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
CN2
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Catalyst Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Catalyst Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Catalyst Pharmaceuticals.

DB:CN2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CN2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:CN2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Catalyst Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:CN2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -21.00 Analyst x1 -19.45
2020 13.00 Analyst x1 11.15
2021 23.00 Analyst x1 18.27
2022 32.00 Analyst x1 23.54
2023 50.00 Analyst x1 34.07
2024 64.28 Est @ 28.56% 40.56
2025 77.18 Est @ 20.06% 45.10
2026 88.07 Est @ 14.11% 47.67
2027 96.83 Est @ 9.95% 48.54
2028 103.64 Est @ 7.03% 48.11
Present value of next 10 years cash flows $297.57
DB:CN2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $103.64 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$1,340.74
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,340.74 ÷ (1 + 7.98%)10
$622.45
DB:CN2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $297.57 + $622.45
$920.01
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $920.01 / 102.80
$8.95
DB:CN2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:CN2 represents 0.86799x of NasdaqCM:CPRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86799x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 8.95 x 0.86799
€7.77
Value per share (EUR) From above. €7.77
Current discount Discount to share price of €4.61
= -1 x (€4.61 - €7.77) / €7.77
40.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Catalyst Pharmaceuticals is available for.
Intrinsic value
41%
Share price is €4.61 vs Future cash flow value of €7.77
Current Discount Checks
For Catalyst Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Catalyst Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Catalyst Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Catalyst Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Catalyst Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CN2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.33
NasdaqCM:CPRX Share Price ** NasdaqCM (2019-04-18) in USD $5.31
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Catalyst Pharmaceuticals.

DB:CN2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CPRX Share Price ÷ EPS (both in USD)

= 5.31 ÷ -0.33

-16.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catalyst Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Catalyst Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Catalyst Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:CN2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
55.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Catalyst Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Catalyst Pharmaceuticals's assets?
Raw Data
DB:CN2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.49
NasdaqCM:CPRX Share Price * NasdaqCM (2019-04-18) in USD $5.31
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:CN2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CPRX Share Price ÷ Book Value per Share (both in USD)

= 5.31 ÷ 0.49

10.74x

* Primary Listing of Catalyst Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catalyst Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Catalyst Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Catalyst Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Catalyst Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Catalyst Pharmaceuticals expected to grow at an attractive rate?
  • Catalyst Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Catalyst Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Catalyst Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CN2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CN2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 55.4%
DB:CN2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 42.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CN2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CN2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 252 142 4
2022-12-31 201 171 4
2021-12-31 146 66 4
2020-12-31 83 19 5
2019-12-31 39 -25 6
DB:CN2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -26 -34
2018-09-30 -21 -25
2018-06-30 -17 -21
2018-03-31 -16 -19
2017-12-31 -14 -18
2017-09-30 -14 -17
2017-06-30 -15 -17
2017-03-31 -16 -18
2016-12-31 -18 -18
2016-09-30 -18 -20
2016-06-30 -20 -20
2016-03-31 -20 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Catalyst Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Catalyst Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CN2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Catalyst Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CN2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.47 1.87 1.06 2.00
2022-12-31 1.11 1.32 0.90 2.00
2021-12-31 0.58 0.75 0.37 3.00
2020-12-31 0.17 0.21 0.12 3.00
2019-12-31 -0.24 -0.13 -0.40 5.00
DB:CN2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.33
2018-09-30 -0.25
2018-06-30 -0.22
2018-03-31 -0.21
2017-12-31 -0.21
2017-09-30 -0.21
2017-06-30 -0.20
2017-03-31 -0.21
2016-12-31 -0.22
2016-09-30 -0.24
2016-06-30 -0.24
2016-03-31 -0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Catalyst Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Catalyst Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Catalyst Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Catalyst Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Catalyst Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Catalyst Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Catalyst Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Catalyst Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Catalyst Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Catalyst Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CN2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.50 -34.00 15.88 19.92
2018-09-30 -24.89 11.06 14.91
2018-06-30 -21.23 9.01 13.07
2018-03-31 -19.15 8.11 11.82
2017-12-31 -18.41 7.30 11.38
2017-09-30 -17.19 6.09 10.79
2017-06-30 -16.96 5.91 10.58
2017-03-31 -17.65 6.49 10.64
2016-12-31 -18.07 7.31 11.37
2016-09-30 -19.72 8.78 12.38
2016-06-30 -20.22 9.33 12.93
2016-03-31 -20.21 9.35 13.00
2015-12-31 -20.23 8.60 11.80
2015-09-30 -17.91 7.84 10.35
2015-06-30 -18.47 7.08 10.20
2015-03-31 -17.11 5.66 9.72
2014-12-31 -15.51 4.47 10.12
2014-09-30 -13.37 3.51 9.80
2014-06-30 -14.28 2.73 9.72
2014-03-31 -14.22 2.36 9.75
2013-12-31 -12.15 2.21 8.10
2013-09-30 -10.88 2.34 6.77
2013-06-30 -7.59 2.52 4.62
2013-03-31 -4.73 2.54 3.02
2012-12-31 -4.08 2.56 2.66
2012-09-30 -6.35 2.88 2.88
2012-06-30 -4.86 2.76 2.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Catalyst Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Catalyst Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Catalyst Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Catalyst Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Catalyst Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Catalyst Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Catalyst Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Catalyst Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Catalyst Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Catalyst Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Catalyst Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Catalyst Pharmaceuticals Company Filings, last reported 3 months ago.

DB:CN2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 50.78 0.00 53.48
2018-09-30 64.08 0.00 61.66
2018-06-30 71.06 0.00 68.41
2018-03-31 76.25 0.00 77.94
2017-12-31 80.96 0.00 84.01
2017-09-30 31.73 0.00 33.91
2017-06-30 33.97 0.00 35.13
2017-03-31 35.10 0.00 36.53
2016-12-31 39.31 0.00 40.41
2016-09-30 42.90 0.00 44.74
2016-06-30 46.33 0.00 48.02
2016-03-31 50.54 0.00 52.45
2015-12-31 55.48 0.00 58.40
2015-09-30 60.65 0.00 62.96
2015-06-30 62.79 0.00 67.40
2015-03-31 66.62 0.00 71.54
2014-12-31 35.24 0.00 39.28
2014-09-30 36.62 0.00 41.45
2014-06-30 41.19 0.00 45.01
2014-03-31 17.64 0.00 21.28
2013-12-31 21.39 0.00 23.71
2013-09-30 22.12 0.00 27.65
2013-06-30 9.84 0.00 11.37
2013-03-31 12.92 0.00 13.16
2012-12-31 14.62 0.00 15.42
2012-09-30 9.39 0.00 11.97
2012-06-30 6.41 0.00 7.51
  • Catalyst Pharmaceuticals has no debt.
  • Catalyst Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Catalyst Pharmaceuticals has sufficient cash runway for 2.1 years based on current free cash flow.
  • Catalyst Pharmaceuticals has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 2.8% each year.
X
Financial health checks
We assess Catalyst Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Catalyst Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Catalyst Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Catalyst Pharmaceuticals dividends.
If you bought €2,000 of Catalyst Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Catalyst Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Catalyst Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CN2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CN2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Catalyst Pharmaceuticals has not reported any payouts.
  • Unable to verify if Catalyst Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Catalyst Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Catalyst Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Catalyst Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Catalyst Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Catalyst Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Catalyst Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pat McEnany
COMPENSATION $900,504
AGE 71
TENURE AS CEO 17.3 years
CEO Bio

Mr. Patrick J. McEnany, also known as Pat, Co-Founded Catalyst Pharmaceutical Partners Inc. in January 2002 and has been its Chairman and President since March 2006 and also its Chief Executive Officer since January 2002. Mr. McEnany served as President of Equisource Capital Inc. from December 1984 to December 1991. From 1973 to 1985, he served as the President, Chief Executive Officer and Chief Financial Officer of Zenex Synthetic Lubricants Inc. From 1999 to 2002, he served as President of AMDG Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., he served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of corporate development for Watson Pharmaceuticals, Inc. From 1991 to April 1997, he served as the Chief Executive Officer of Royce Laboratories, Inc. He served as President of Royce Laboratories, Inc. since June 1991 until April 1997. He served as the Chief Operating Officer of Royce Laboratories, Inc. He served as the Chairman of Royce Laboratories Inc. since February 1994. From 1993 to 1997, he served as the Vice Chairman of the National Association of Pharmaceutical Manufacturers. He was a founder of Maidstone Capital, Inc., which reorganized with Check Express Inc.'s predecessors in 1988. He serves as Director of Renal CarePartners, Inc. He has been Director of Catalyst Pharmaceutical Partners Inc. since January 2002. He serves as a Director of the Jackson Memorial Hospital Foundation, located in Miami, Florida. He served as Director of Home Intensive Care, Inc. He served as a Director of Cesca Therapeutics Inc. since 1997 until June 19, 2015 and served as its Lead Independent Director until June 15, 2015. Mr. McEnany served as a Director of Cesca Therapeutics Inc. from 1985 to 1991 and National Association of Pharmaceutical Manufacturers from 1993 to 1997. He served as an Outside Director of Check Express Inc. since April 1988. He served as a Director of Royce Laboratories, Inc. since 1990. Mr. McEnany served as a Director of Med/waste, Inc. from March 2000 to 2002.

CEO Compensation
  • Pat's compensation has increased whilst company is loss making.
  • Pat's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Catalyst Pharmaceuticals management team in years:

3.5
Average Tenure
59
Average Age
  • The tenure for the Catalyst Pharmaceuticals management team is about average.
Management Team

Pat McEnany

TITLE
Co-Founder
COMPENSATION
$901K
AGE
71
TENURE
17.3 yrs

Alicia Grande

TITLE
VP, Treasurer & CFO
COMPENSATION
$524K
AGE
47
TENURE
7.3 yrs

Steve Miller

TITLE
COO & Chief Scientific Officer
COMPENSATION
$607K
AGE
56
TENURE
8.3 yrs

Brian Elsbernd

TITLE
Chief Legal & Compliance Officer
COMPENSATION
$353K
AGE
54
TENURE
3.2 yrs

Gary Ingenito

TITLE
Chief Medical Officer & Head of Regulatory Affairs
COMPENSATION
$595K
AGE
62
TENURE
3.8 yrs

Jeff Carmen

TITLE
Senior Vice President of Sales & Marketing
TENURE
0.7 yrs

Dan Brennan

TITLE
Chief Commercial Officer
AGE
50
TENURE
0.8 yrs

Jason James

TITLE
Senior Vice President of Commercial Operations & Analytics
TENURE
0.7 yrs

Phil Schwartz

TITLE
Corporate Secretary
AGE
63

Chuck Gorodetzky

TITLE
Consultant
AGE
80
Board of Directors Tenure

Average tenure and age of the Catalyst Pharmaceuticals board of directors in years:

8.4
Average Tenure
71.5
Average Age
  • The tenure for the Catalyst Pharmaceuticals board of directors is about average.
Board of Directors

Pat McEnany

TITLE
Co-Founder
COMPENSATION
$901K
AGE
71
TENURE
13.1 yrs

David Tierney

TITLE
Director
COMPENSATION
$98K
AGE
54
TENURE
16.5 yrs

Jonathan Brodie

TITLE
Chairman of Scientific Advisory Board

Don Denkhaus

TITLE
Director
COMPENSATION
$101K
AGE
72
TENURE
4.2 yrs

Charles O'Keeffe

TITLE
Lead Independent Director
COMPENSATION
$120K
AGE
78
TENURE
7.8 yrs

Eugene Laska

TITLE
Member of Scientific Advisory Board

Robert Fechtner

TITLE
Member of Scientific Advisory Board

Phil Coelho

TITLE
Director
COMPENSATION
$98K
AGE
74
TENURE
16.5 yrs

Richard Silverman

TITLE
Member of Scientific Advisory Board
TENURE
8.4 yrs

Rich Daly

TITLE
Director
COMPENSATION
$92K
AGE
57
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Dec 18 Buy Donald Denkhaus Individual 27. Dec 18 27. Dec 18 25,000 €1.67 €41,853
19. Dec 18 Buy Patrick McEnany Individual 19. Dec 18 19. Dec 18 20,000 €1.96 €39,209
17. Dec 18 Buy Donald Denkhaus Individual 14. Dec 18 14. Dec 18 60,000 €2.20 €131,748
14. Dec 18 Buy Charles O'Keeffe Individual 14. Dec 18 14. Dec 18 20,000 €2.21 €44,270
11. Jun 18 Buy Donald Denkhaus Individual 08. Jun 18 08. Jun 18 20,000 €2.90 €57,990
08. Jun 18 Buy Charles O'Keeffe Individual 07. Jun 18 07. Jun 18 1,000 €2.84 €2,835
07. Jun 18 Buy Charles O'Keeffe Individual 07. Jun 18 07. Jun 18 4,000 €2.80 €11,182
01. Jun 18 Buy Charles O'Keeffe Individual 01. Jun 18 01. Jun 18 5,000 €3.20 €16,005
31. May 18 Buy Donald Denkhaus Individual 30. May 18 30. May 18 20,000 €3.22 €64,470
X
Management checks
We assess Catalyst Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Catalyst Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Details
Name: Catalyst Pharmaceuticals, Inc.
CN2
Exchange: DB
Founded: 2002
$485,405,925
102,804,257
Website: http://www.catalystpharma.com
Address: Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle,
Suite 1250,
Coral Gables,
Florida, 33134,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CPRX Common Stock Nasdaq Capital Market US USD 08. Nov 2006
DB CN2 Common Stock Deutsche Boerse AG DE EUR 08. Nov 2006
Number of employees
Current staff
Staff numbers
51
Catalyst Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:29
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.